Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world observational study of brentuximab vedotin in CD30-positive lymphoma in China
ChiCTR2100046036Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brentuximab vedotin in CD30-positive lymphoma, sponsored by Ruijin Hospital. Primary endpoint: Serious adverse events. Started Dec 2020; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
CD30-positive lymphoma
Beyond the preview
Go deeper on ChiCTR2100046036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046036.